title: Innate immune response to La Crosse virus infection.
abstract: Viral encephalitis represents a significant, and costly, public health threat particularly for high-risk pediatric populations. An emerging mosquito-borne pathogen endemic to the United States, La Crosse virus (LACV) is one of the most common causes of viral encephalitis in children in the United States. However, no licensed therapeutics or vaccines currently exist for treatment. Hampering development efforts, the host response to LACV and its role in disease pathogenesis has only recently been examined. In this review, we discuss the current understanding of innate immune response in the context of viral pathogenesis and host susceptibility to LACV. In addition, we address the need for a clearer understanding of the early host-virus interactions in LACV infections as it relates to viral pathogenesis in the central nervous system.
authors.affiliation: Rocky Mountain Laboratories, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, 903 S 4th St, Hamilton, MT, 59840, USA, katherine.taylor@nih.gov.
authors.forename: Katherine G
authors.initials: KG
authors.lastname: Taylor
authors.forename: Karin E
authors.initials: KE
authors.lastname: Peterson
mesh_terms: D000330:Aedes / Q000821:virology; D000818:Animals; D002490:Central Nervous System / Q000276:immunology* / Q000473:pathology / Q000821:virology; D002648:Child; D004197:Disease Reservoirs / Q000662:veterinary* / Q000821:virology; D004198:Disease Susceptibility; D004199:Disease Vectors; D004670:Encephalitis, California / Q000276:immunology* / Q000473:pathology / Q000635:transmission / Q000821:virology; D058507:Host Specificity; D054884:Host-Pathogen Interactions; D006801:Humans; D007113:Immunity, Innate; D007370:Interferon Type I / Q000096:biosynthesis; D018062:La Crosse virus / Q000276:immunology*; D051379:Mice
chemical_list: D007370:Interferon Type I